A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys
- 30 September 2010
- journal article
- Published by Elsevier BV in Neurobiology of Disease
- Vol. 39 (3), 352-361
- https://doi.org/10.1016/j.nbd.2010.05.001
Abstract
No abstract availableFunding Information
- Michael J. Fox Foundation for Parkinson's Research
- Swedish National Research Council and European Community (222918)
This publication has 65 references indexed in Scilit:
- Dopamine receptors and l-dopa-induced dyskinesiaParkinsonism & Related Disorders, 2009
- Striatal Overexpression of ΔJunD Resets L-DOPA-Induced Dyskinesia in a Primate Model of Parkinson DiseaseBiological Psychiatry, 2009
- A pilot open label, single dose trial of fenobam in adults with fragile X syndromeJournal of Medical Genetics, 2009
- Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's diseaseNeurobiology of Disease, 2006
- l-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brainNeurobiology of Disease, 2005
- Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEPBrain Research, 2005
- Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesiaAnnals of Neurology, 2004
- Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor functionNature Medicine, 2003
- Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's DiseaseJournal of Neuroscience, 2001
- Pathophysiology of levodopa-induced dyskinesia: Potential for new therapiesNature Reviews Neuroscience, 2001